Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

HepatitisHepatology

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Lancet Gastroenterol Hepatol.

Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M

doi: 10.1016/S2468-1253

Hepatology

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

BMC Gastroenterol.

Liang Y, Li D

doi: 10.1186/s12876-020-01234-x.

Hepatology

Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease

J Gastroenterol.

Kakisaka K, Suzuki Y, Fujiwara Y, Abe T, Yonezawa M, Kuroda H, Ishida K, Sugai T, Takikawa Y

doi: 10.1007/s00535-018-1468-9.

Hepatology

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

BMC Gastroenterol.

Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A

doi: 10.1186/s12876-019-1055-4.

Hepatology

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol.

Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH

doi: 10.1016/S2468-1253(20)30077-7.

Hepatology

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

BMC Gastroenterol

Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH

doi: 10.1186/s12876-021-01660-5

Hepatology

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

J Hepatol.

Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V

doi: 10.1016/j.jhep.2019.12.008.

Hepatology

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

J Gastroenterol Hepatol.

Gao F, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH

doi: 10.1111/jgh.15112.

Related content

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients

A randomised placebo controlled trial of VSL#3^® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease